- O-1.53%
BlockBeats News, August 20th, according to BIT (bit.com) market data, Moderna (MRNA.O) dropped by 16%, after a more than 170% surge in the previous day's close.
Earlier reports stated that the personalized mRNA cancer vaccine jointly developed by Moderna and Merck showed significant success in a Phase 3 clinical trial for high-risk melanoma. This marks the world's first mRNA cancer therapy to demonstrate effectiveness in a large-scale Phase 3 trial. Following this announcement, Moderna's stock price skyrocketed by nearly 177% in a single day.
Disclaimer: Konten ini berasal dari pihak lain atau diterjemahkan oleh AI dari pihak lain. CoinEx tidak menjamin konten ini benar, asli, atau akurat, dan tidak memberikan saran investasi. Harga aset kripto sangat tidak stabil, jadi harap berhati-hati terhadap risiko yang ada.
- KriptoHargaPerubahan 24J